, 12:116 | Cite as

Androgen deficiency: effects on body composition

  • Karen K. MillerEmail author


Published data on the effects of androgen deficiency and testosterone administration on body composition in men and women are reviewed. In experimental paradigms, androgen deprivation decreases lean body mass and increases fat mass in men, and physiologic replacement reverses these abnormalities. The anabolic effects of testosterone administration on muscle in men are well-established, and current understanding of the underlying mechanisms are discussed. Randomized, placebo-controlled studies have been performed to investigate the effects of testosterone administration on body composition in a number of male hypogonadal states, including HIV-associated weight loss, supraphysiologic glucocorticoid administration, aging and obesity, with variable outcomes, and the results are reviewed. There are few data investigating the effects of hypoandrogenemia or androgen replacement on body composition in women, in whom endogenous testosterone levels are a fraction of those in men. A recent randomized, placebo-controlled study of physiologic testosterone replacement therapy in women with profound hypoandrogenemia due to hypopituitarism demonstrated an increase in skeletal muscle mass but no change in body fat. Further research is needed to establish the effects of endogenous androgens on the regulation of body composition in women.


Testosterone Body composition 


  1. 1.
    Brown-Sequard CE (1889) Note on the effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. Lancet 2:105–107CrossRefGoogle Scholar
  2. 2.
    Cussons AJ, Bhagat CI, Fletcher SJ, Walsh JP (2002) Brown-Sequard revisited: a lesson from history on the placebo effect of androgen treatment. Med J Aust 177:678–679PubMedGoogle Scholar
  3. 3.
    Freeman ER, Bloom DA, McGuire EJ (2001) A brief history of testosterone. J Urol 165:371–373. doi: 10.1097/00005392-200102000-00004 PubMedCrossRefGoogle Scholar
  4. 4.
    Butenandt A, Hanisch G (1935) Umwandlung des dehydro-androsterons in androsendiol und testosteron; ein weg zur darstellung des testosterons aus cholestrin. Hoppe Seylers Z Physiol Chem 237:89Google Scholar
  5. 5.
    Ruzicka L, Wettstein A (1935) Sexualhormone VII. Uber die kunstliche herstellung des testikelhormons. Testosteron (androsten-3-on-17-ol.). Helv Chim Acta 18:1264. doi: 10.1002/hlca.193501801176 CrossRefGoogle Scholar
  6. 6.
    Wilson JD (1988) Androgen abuse by athletes. Endocr Rev 9:181–199PubMedCrossRefGoogle Scholar
  7. 7.
    Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81:4358–4365. doi: 10.1210/jc.81.12.4358 PubMedCrossRefGoogle Scholar
  8. 8.
    Katznelson L, Rosenthal D, Rosol M et al (1997) Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR Am J Roentgenol 170:423–427Google Scholar
  9. 9.
    Woodhouse LJ, Gupta N, Bhasin M et al (2004) Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab 89:718–726. doi: 10.1210/jc.2003-031492 PubMedCrossRefGoogle Scholar
  10. 10.
    Mauras N, Hayes V, Welch S et al (1998) Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 83:1886–1892. doi: 10.1210/jc.83.6.1886 PubMedCrossRefGoogle Scholar
  11. 11.
    Galvao DA, Spry NA, Taaffe DR et al (2008) Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int [Epub ahead of print]Google Scholar
  12. 12.
    Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ (2003) Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88:3167–3176. doi: 10.1210/jc.2002-021827 PubMedCrossRefGoogle Scholar
  13. 13.
    Reid IR, Wattie DJ, Evans MC, Stapleton JP (1996) Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156:1173–1177. doi: 10.1001/archinte.156.11.1173 PubMedCrossRefGoogle Scholar
  14. 14.
    Bhasin S, Storer TW, Asbel-Sethi N et al (1998) Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 83:3155–3162. doi: 10.1210/jc.83.9.3155 PubMedCrossRefGoogle Scholar
  15. 15.
    Bhasin S, Storer TW, Javanbakht M et al (2000) Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283:763–770. doi: 10.1001/jama.283.6.763 PubMedCrossRefGoogle Scholar
  16. 16.
    Grinspoon S, Corcoran C, Askari H et al (1998) Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129:18–26PubMedGoogle Scholar
  17. 17.
    Grinspoon S, Corcoran C, Parlman K et al (2000) Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 133:348–355PubMedGoogle Scholar
  18. 18.
    Coodley GO, Coodley MK (1997) A trial of testosterone therapy for HIV-associated weight loss. AIDS 11:1347–1352. doi: 10.1097/00002030-199711000-00008 PubMedCrossRefGoogle Scholar
  19. 19.
    Dobs AS, Cofrancesco J, Nolten WE et al (1999) The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med 107:126–132. doi: 10.1016/S0002-9343(99)00193-X PubMedCrossRefGoogle Scholar
  20. 20.
    Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S (2006) Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr 41:304–314. doi: 10.1097/01.qai.0000197546.56131.40 PubMedCrossRefGoogle Scholar
  21. 21.
    Storer TW, Woodhouse LJ, Sattler F et al (2005) A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab 90:4474–4482. doi: 10.1210/jc.2005-0275 PubMedCrossRefGoogle Scholar
  22. 22.
    Bhasin S, Calof OM, Storer TW et al (2006) Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2:146–159. doi: 10.1038/ncpendmet0120 PubMedCrossRefGoogle Scholar
  23. 23.
    Feldman HA, Longcope C, Derby CA et al (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87:589–598. doi: 10.1210/jc.87.2.589 PubMedCrossRefGoogle Scholar
  24. 24.
    Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724–731. doi: 10.1210/jc.86.2.724 PubMedCrossRefGoogle Scholar
  25. 25.
    Bhasin S, Woodhouse L, Casaburi R et al (2005) Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90:678–688. doi: 10.1210/jc.2004-1184 PubMedCrossRefGoogle Scholar
  26. 26.
    Page ST, Amory JK, Bowman FD et al (2005) Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502–1510. doi: 10.1210/jc.2004-1933 PubMedCrossRefGoogle Scholar
  27. 27.
    Snyder PJ, Peachey H, Hannoush P et al (1999) Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84:2647–2653. doi: 10.1210/jc.84.8.2647 PubMedCrossRefGoogle Scholar
  28. 28.
    Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 58:618–625PubMedGoogle Scholar
  29. 29.
    Blackman MR, Sorkin JD, Munzer T et al (2002) Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288:2282–2292. doi: 10.1001/jama.288.18.2282 PubMedCrossRefGoogle Scholar
  30. 30.
    Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG (2001) Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 56:M266–M272PubMedGoogle Scholar
  31. 31.
    Tenover JS (1992) Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75:1092–1098. doi: 10.1210/jc.75.4.1092 PubMedCrossRefGoogle Scholar
  32. 32.
    Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R (2003) AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88:2673–2681. doi: 10.1210/jc.2002-021058 PubMedCrossRefGoogle Scholar
  33. 33.
    Harman SM, Blackman MR (2003) The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men. Horm Res 60:121–124. doi: 10.1159/000071236 PubMedCrossRefGoogle Scholar
  34. 34.
    Morley JE, Perry HM III, Kaiser FE et al (1993) Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 41:149–152PubMedGoogle Scholar
  35. 35.
    Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C (1997) Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 82:1661–1667. doi: 10.1210/jc.82.6.1661 PubMedCrossRefGoogle Scholar
  36. 36.
    Calof OM, Singh AB, Lee ML et al (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60:1451–1457PubMedGoogle Scholar
  37. 37.
    Barrett-Connor E, Khaw KT (1988) Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78:539–545PubMedGoogle Scholar
  38. 38.
    Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R (1990) Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 39:897–901. doi: 10.1016/0026-0495(90) 90297-P PubMedCrossRefGoogle Scholar
  39. 39.
    Zumoff B (1988) Hormonal abnormalities in obesity. Acta Med Scand Suppl 723:153–160PubMedGoogle Scholar
  40. 40.
    Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB (2006) Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91:843–850. doi: 10.1210/jc.2005-1326 PubMedCrossRefGoogle Scholar
  41. 41.
    Laaksonen DE, Niskanen L, Punnonen K et al (2004) Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036–1041. doi: 10.2337/diacare.27.5.1036 PubMedCrossRefGoogle Scholar
  42. 42.
    Oh JY, Barrett-Connor E, Wedick NM, Wingard DL (2002) Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 25:55–60. doi: 10.2337/diacare.25.1.55 PubMedCrossRefGoogle Scholar
  43. 43.
    Laaksonen DE, Niskanen L, Punnonen K et al (2005) The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 90:712–719. doi: 10.1210/jc.2004-0970 PubMedCrossRefGoogle Scholar
  44. 44.
    Marin P, Holmang S, Jonsson L et al (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16:991–997PubMedGoogle Scholar
  45. 45.
    Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS (2001) Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 111:261–269. doi: 10.1016/S0002-9343(01)00833-6 PubMedCrossRefGoogle Scholar
  46. 46.
    Laughlin GA, Barrett-Connor E, Bergstrom J (2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93:68–75. doi: 10.1210/jc.2007-1792 PubMedCrossRefGoogle Scholar
  47. 47.
    Khaw KT, Dowsett M, Folkerd E et al (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116:2694–2701. doi: 10.1161/CIRCULATIONAHA.107.719005 PubMedCrossRefGoogle Scholar
  48. 48.
    Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB (2007) Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 167:1252–1260. doi: 10.1001/archinte.167.12.1252 PubMedCrossRefGoogle Scholar
  49. 49.
    Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P (2005) Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation 112:332–340. doi: 10.1161/CIRCULATIONAHA.104.489088 PubMedCrossRefGoogle Scholar
  50. 50.
    Snyder PJ (2008) Might testosterone actually reduce mortality? J Clin Endocrinol Metab 93:32–33. doi: 10.1210/jc.2007-2506 PubMedCrossRefGoogle Scholar
  51. 51.
    Miller KK, Rosner W, Lee H et al (2004) Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab 89:525–533. doi: 10.1210/jc.2003-030680 PubMedCrossRefGoogle Scholar
  52. 52.
    Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H (2007) Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92:405–413. doi: 10.1210/jc.2006-1864 PubMedCrossRefGoogle Scholar
  53. 53.
    Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ (2007) Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 92:3040–3043. doi: 10.1210/jc.2007-0581 PubMedCrossRefGoogle Scholar
  54. 54.
    Judd HL, Judd GE, Lucas WE, Yen SS (1974) Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 39:1020–1024PubMedGoogle Scholar
  55. 55.
    Judd HL, Lucas WE, Yen SS (1974) Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 118:793–798PubMedGoogle Scholar
  56. 56.
    Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D (2000) Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 85:645–651. doi: 10.1210/jc.85.2.645 PubMedCrossRefGoogle Scholar
  57. 57.
    Shifren JL, Braunstein GD, Simon JA et al (2000) Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343:682–688. doi: 10.1056/NEJM200009073431002 PubMedCrossRefGoogle Scholar
  58. 58.
    Arlt W, Callies F, van Vlijmen JC et al (1999) Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 341:1013–1020. doi: 10.1056/NEJM199909303411401 PubMedCrossRefGoogle Scholar
  59. 59.
    Kim MH, Rosenfield RL, Dupon C (1976) The effects of dexamethasone on plasma free androgens during the normal menstrual cycle. Am J Obstet Gynecol 126:982–986PubMedGoogle Scholar
  60. 60.
    Mathur RS, Landgrebe SC, Moody LO, Semmens JP, Williamson HO (1985) The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women. Maturitas 7:129–133. doi: 10.1016/0378-5122(85)90018-0 PubMedCrossRefGoogle Scholar
  61. 61.
    Dor J, Bider D, Shulman A et al (2000) Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro-results of a prospective, randomized in-vitro fertilization study. Hum Reprod 15:1225–1230. doi: 10.1093/humrep/15.6.1225 PubMedCrossRefGoogle Scholar
  62. 62.
    Miller KK, Lawson EA, Mathur V et al (2007) Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. J Clin Endocrinol Metab 92:1334–1339. doi: 10.1210/jc.2006-2501 PubMedCrossRefGoogle Scholar
  63. 63.
    Miller K, Corcoran C, Armstrong C et al (1998) Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 83:2717–2725. doi: 10.1210/jc.83.8.2717 PubMedCrossRefGoogle Scholar
  64. 64.
    Zumoff B, Strain GW, Miller LK, Rosner W (1995) Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 80:1429–1430. doi: 10.1210/jc.80.4.1429 PubMedCrossRefGoogle Scholar
  65. 65.
    Miller KK, Sesmilo G, Schiller A, Schoenfeld D, Burton S, Klibanski A (2001) Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab 86:561–567. doi: 10.1210/jc.86.2.561 PubMedCrossRefGoogle Scholar
  66. 66.
    Dolan S, Wilkie S, Aliabadi N et al (2004) Effects of testosterone administration in human immunodeficiency virus-infected women with low weight: a randomized placebo-controlled study. Arch Intern Med 164:897–904. doi: 10.1001/archinte.164.8.897 PubMedCrossRefGoogle Scholar
  67. 67.
    Choi HH, Gray PB, Storer TW et al (2005) Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss. J Clin Endocrinol Metab 90:1531–1541. doi: 10.1210/jc.2004-1677 PubMedCrossRefGoogle Scholar
  68. 68.
    Miller KK, Biller BM, Beauregard C et al (2006) Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 91:1683–1690. doi: 10.1210/jc.2005-2596 PubMedCrossRefGoogle Scholar
  69. 69.
    Miller KK, Biller BM, Schaub A et al (2007) Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. J Clin Endocrinol Metab 92:2474–2479. doi: 10.1210/jc.2007-0195 PubMedCrossRefGoogle Scholar
  70. 70.
    Brodsky IG, Balagopal P, Nair KS (1996) Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 81:3469–3475. doi: 10.1210/jc.81.10.3469 PubMedCrossRefGoogle Scholar
  71. 71.
    Urban RJ, Bodenburg YH, Gilkison C et al (1995) Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 269:E820–E826PubMedGoogle Scholar
  72. 72.
    Sinha-Hikim I, Artaza J, Woodhouse L et al (2002) Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 283:E154–E164PubMedGoogle Scholar
  73. 73.
    Singh AB, Hsia S, Alaupovic P et al (2002) The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 87:136–143. doi: 10.1210/jc.87.1.136 PubMedCrossRefGoogle Scholar
  74. 74.
    Singh R, Artaza JN, Taylor WE et al (2006) Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147:141–154. doi: 10.1210/en.2004-1649 PubMedCrossRefGoogle Scholar
  75. 75.
    Bhasin S, Taylor WE, Singh R et al (2003) The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 58:M1103–M1110PubMedGoogle Scholar
  76. 76.
    Bhasin S, Cunningham GR, Hayes FJ et al (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91:1995–2010. doi: 10.1210/jc.2005-2847 PubMedCrossRefGoogle Scholar
  77. 77.
    Braunstein GD, Sundwall DA, Katz M et al (2005) Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 165:1582–1589. doi: 10.1001/archinte.165.14.1582 PubMedCrossRefGoogle Scholar
  78. 78.
    Buster JE, Kingsberg SA, Aguirre O et al (2005) Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 105:944–952PubMedGoogle Scholar
  79. 79.
    Davis SR, van der Mooren MJ, van Lunsen RH et al (2006) Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 13:387–396. doi: 10.1097/01.gme.0000179049.08371.c7 PubMedCrossRefGoogle Scholar
  80. 80.
    Simon J, Braunstein G, Nachtigall L et al (2005) Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 90:5226–5233. doi: 10.1210/jc.2004-1747 PubMedCrossRefGoogle Scholar
  81. 81.
    Shifren JL, Davis SR, Moreau M et al (2006) Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 13:770–779. doi: 10.1097/01.gme.0000227400.60816.52 PubMedCrossRefGoogle Scholar
  82. 82.
    Wierman ME, Basson R, Davis SR et al (2006) Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 91:3697–3710. doi: 10.1210/jc.2006-1121 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Neuroendocrine UnitMassachusetts General Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations